Researchers presented late breaking five-year data from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) trial, a prospective, randomized trial comparing initial therapy with the steroidal aromatase inhibitor exemestane vs. a switch from initial therapy of tamoxifen to exemestane after a few years "This is the only aromatase inhibitor study that has used exemestane as initial endocrine therapy compared to tamoxifen followed by exemestane," said study author Daniel Rea, M.D., senior lecturer in medical oncology at the University of Birmingham, United Kingdom. "This is also the only study with sufficient power to reliably determine if an aromatase inhibitor as initial therapy is superior to a sequential approach starting with tamoxifen."